Skip to content
AdminAug 5, 2018< 1 min read

US FDA wants more examples of real-world data use

The FDA is cautious about solely relying on real-world evidence for drug label indications but supports experiments to bridge the gap, as demonstrated by a pilot project initiated by the Friends of Cancer Research, aiming to establish best practices and standards for incorporating real-world evidence into drug development and regulatory decision-making processes.

Read More

RELATED ARTICLES